Regencell Bioscience Holdings Limited (RGC)
NEUTRALFundamental
66
Price
$5.55
Market Cap
-
Part 1 · What the company is worth
Overview
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$3.16B
Trailing 12 months (through 12/31/2017)
Net Income
$112M
Trailing 12 months (through 12/31/2017)
Free Cash Flow
-
Total Equity
$-856M
Total Liabilities
$3.70B
Current Ratio
0.83
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$3.74
Current Price
$5.55
Margin of Safety
-48.3%
Fair Value Range
$3.55 - $3.93
Estimation Methods
Valuation Metrics
P/E Ratio
7.35
ROE
-13.1%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
9.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
9.4%
WACC
11.6%
ROIC − WACC
-2.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (11)
- EPS shows upward trend
- EPS CAGR 18.50%
- Price CAGR 44.61%
- ROIC 9.4%
- Operating Margin 8.6%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/NI) 3.65
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Failed (3)
- DCF valuation (Unknown)
- ROE -231.9%
- Net Margin Trend 3.6% vs 5.3%
Unavailable (14)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 52 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | - |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 47 |
| Ms. Antonia Assang | Senior Vice President of Project Management | - |
| Mr. Yat-Pui Au | Chief Business Officer | 50 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for RGC, sourced from Markets Gazette.
- 3/5/2026NEGATIVEDon't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
The article warns investors against buying Regencell Bioscience stock (RGC), highlighting a critical "red flag." While the company is exploring Traditional Chinese Medicine (TCM) opportunities, the exact nature and viability of these ventures remain unclear. This lack of transparency or concrete details regarding Regencell Bioscience's TCM strategies poses a significant risk. For investors, this indicates high uncertainty and potential undisclosed issues, making the stock unsuitable for speculative investment until operational details and market potential are clarified.
- 3/1/2026NEGATIVEForget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
A recent financial analysis article advises investors to disregard general market sentiment concerning Regencell Bioscience Holdings Limited. While not providing specific details, the analysis casts the company in an unfavorable light, suggesting to "forget" it in favor of an unspecified blue-chip drug maker, described as a "boring compounder" that investors need. This implies a cautious or negative outlook on Regencell, suggesting its prospects might not be as promising as market perception, or that more solid, less volatile alternatives exist. Investors should consider this as a potential red flag, prompting further due diligence on the company before making investment decisions.
via Markets Gazette